

Luxembourg

Population (January 2013):	537 039
Human Development Index (2013):	0.881
HAV vaccine recommendations:	Hepatitis A vaccine is not part of the routine childhood immunisation programme. The vaccine is recommended for: <ol style="list-style-type: none"> 1. child-care workers and workers in collective institutions 2. personnel in the food sector 3. personnel in water-treatment plants 4. travellers to endemic countries.
Seroprevalence studies by quality score:	score 0: 0 study score 1: 1 study score 2: 0 studies
Seroprevalence studies timeframe:	2000–2001

Seroprevalence assessment: **very low**
 Incidence assessment: **very low**
 Susceptibility in adults: **high**

The only study published in Luxembourg (Mossong 2006) reported seroprevalence in 2001 below 50% in all age groups considered; seroprevalence was less than 20% up to 19 years of age. No other study was available. According to the available data Luxembourg should be considered a very low endemicity country.

Luxembourg_Table 1. Hepatitis A seroprevalence level by time period

	Very low endemicity	Low endemicity	Intermediate endemicity
1975–1989			
1990–1999			
2000–2013			

As TESSy data show, reported hepatitis A incidence between 2006 and 2012 was below 1 case per 100 000; according to Nothdruff (2007). The country experienced some disease outbreaks during the 1990's. The current level of incidence is in line with the very low endemicity level assessed through the seroprevalence survey in 2001.

The susceptibility among adults is high, with more than 60% susceptible individuals by age 30, and about 50% by the age of 50.

Luxembourg_Figure 1 (panel a). Summary of seroprevalence in Luxembourg, by age and time period.


Panel a.1: 1975–1989

No data available


Panel a.2: 1990–1999

No data available

Panel a.3: 2000–2013



Luxembourg_Figure 2. Reported incidence of hepatitis A, Luxembourg, 1990–2013



Bibliography

1. Mossong J, Putz L, Patiny S, Schneider F. Seroepidemiology of hepatitis A and hepatitis B virus in Luxembourg. *Epidemiol Infect.* 2006 Aug;134(4):808-13.
2. Nothdurft HD, Dahlgren AL, Gallagher EA, Kollaritsch H, Overbosch D, Rummukainen ML, et al. The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern Europe and non-European Mediterranean countries: Review and consensus statement on hepatitis A and B vaccination. *J Travel Med.* 2007;14(3):181-7.